Cetero Research Announces More Than 500 Diabetes Studies Completed
Cetero Research announced it has completed more than 500 diabetes research studies in the past three years for both Type 1 and Type 2 diabetics, including complex clamp studies and studies in Phase I, II, III and IV. Cetero combines both pivotal pharmacokinetic studies and proof-of-concept studies in one study.
“Approximately eight percent of the U.S. population struggles with diabetes, and the numbers continue to grow,” said Dr. Troy McCall, CEO of Cetero Research. “According to the Pharmaceutical Research and Manufacturers of America (PhRMA), there are a record number of diabetes drugs in development to help the 20 million Americans battling this disease every day. We want to help get those treatments through proof-of-concept faster by providing a full range of services to pharmaceutical companies.”
Cetero runs first-in-human, pharmacokinetic, and proof-of concept studies in diabetics across three of its clinical facilities.
In one diabetes study for a global pharmaceutical company, Cetero randomized the first subject about three weeks after screening began. The final one of the 56 subjects was randomized 13 weeks after the first screening.
Cetero maintains recruiting strategies to build their database of potential study participants. These factors ensure studies are fully recruited, and start and conclude on-time. Cetero also works with a large endocrinology physician practice, which provides Cetero and its clients with access to additional patients.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
